Reversing Immunosenescence: mRNA Technology Turns the Liver into an Immune Factor Factory

Forum topic · ✨步子哥 · 2026-01-14

Summary

This forum post analyzes a Nature-published study from Feng Zhang's team showing that lipid nanoparticle (LNP)-delivered mRNA encoding three immune factors—DLL1, FLT3L, and IL-7 (the DFI cocktail)—can partially rejuvenate the aged immune system. The strategy exploits the liver's natural propensity to take up intravenously injected LNPs (over 80% accumulate there), using hepatocytes as a temporary factory that secretes immune-nourishing factors into the bloodstream. Unlike conventional mRNA vaccines that encode pathogen antigens, this approach delivers transient, physiological immune modulation without encoding foreign antigens. In aged mice (18-22 months), four weeks of DFI treatment restored naive T cell numbers and TCR diversity, roughly rejuvenating immunity by six months; doubled vaccine-specific CD8+ T cell responses; and achieved complete melanoma tumor regression in 40% of treated animals, with synergy with checkpoint inhibitors. No severe autoimmunity was observed, including in diabetes-prone NOD mice, and effects were reversible after stopping treatment. The post explains the mechanisms of immunosenescence (thymic involution, inflammaging, declining TCR diversity, immune tolerance imbalance), why the liver is an ideal delivery target, and outlines remaining challenges: mouse-to-human translation, LNP optimization, dosing, long-term safety monitoring, and regulatory pathways.

This article reviews a recent Nature study from Feng Zhang's team demonstrating that mRNA technology can partially reverse immunosenescence by turning the liver into a temporary "immune factor factory."

Key points

Immunosenescence mechanisms: The aging immune system suffers from thymic involution (near-total loss of new T cell production by ~75), declining naive T cell output and TCR diversity, functional decline of T/B/DC/NK cells, chronic low-grade inflammation (inflammaging with elevated IL-6, TNF-α, CRP), and immune tolerance imbalance raising autoimmune risk.
Why the liver: Hepatocytes retain robust protein synthesis capacity even in old age; intravenous LNPs preferentially accumulate in the liver (>80%) via ApoE/LDLR-mediated uptake; and the liver's central position in blood circulation allows secreted factors to rapidly reach the whole immune system.
The DFI mRNA cocktail: A single LNP co-delivers mRNAs encoding three factors that decline with age:
DLL1 — Notch ligand that drives lymphoid progenitors toward the T cell lineage
FLT3L — expands dendritic cells and lymphoid progenitors
IL-7 — survival and homeostatic signal for T cells

How it differs from existing approaches

Reported results in aged mice (18–22 months)

Increased common lymphoid progenitors, restored thymopoiesis, elevated naive T cell counts; estimated immune rejuvenation of ~24 weeks (~6 months)
Vaccine response: ~2x more antigen-specific CD8+ T cells, restored TCR diversity
B16 melanoma model: 40% complete tumor regression (vs. 0% in controls); synergy with PD-L1 checkpoint blockade
Safety: no severe autoimmune reactions (tested even in diabetes-prone NOD mice); effects faded 4 weeks after stopping, indicating reversibility

Translational outlook

Could improve elderly vaccine responses (flu, COVID-19) and boost responses to checkpoint inhibitors in older cancer patients
Remaining challenges: mouse-to-human translation, LNP targeting/dosing optimization, long-term safety monitoring, and lengthy regulatory/clinical trial pathways (I–III phases, often >10 years)

*Note: All results described are from mouse studies; no human efficacy or safety data exist yet.*